EBS|Emergent BioSolutions Inc|株価:7.930|変動率:-0.14

詳細情報 Emergent BioSolutions Inc 企業名

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Emergent BioSolutions Incの企業情報



企業コードEBS

会社名Emergent BioSolutions Inc

上場日Nov 15, 2006

最高経営責任者「CEO」Papa (Joseph C)

従業員数900

証券種類Ordinary Share

決算期末Nov 15

本社所在地300 Professional Dr

都市GAITHERSBURG

証券取引所NASDAQ OMX NASDAQ Basic NYSE

国United States of America

郵便番号20879

電話番号12406313200

ウェブサイトhttps://emergentbiosolutions.com/

企業コードEBS

上場日Nov 15, 2006

最高経営責任者「CEO」Papa (Joseph C)

Emergent BioSolutions Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

117.11K

-192.46%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

109.24K

-32.46%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

89.33K

-15.85%

Mr. Ronald B. Richard

Independent Director

64.02K

-22.12%

Ms. Jessica Perl

Senior Vice President, General Counsel, Corporate Secretary

61.00K

-10.60%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

55.82K

-5.97%

Mr. Marvin L. White

Independent Director

54.09K

-26.17%

Mr. Keith A. Katkin, CPA

Independent Director

49.16K

-34.52%

Mr. William Hartzel

Senior Vice President - Manufacturing and Bioservices

46.66K

-20.35%

Dr. Simon C Lowry, M.D.

Chief Medical Officer, Head of Research and Development

16.48K

-436.55%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Joseph C. (Joe) Papa

President, Chief Executive Officer, Director

117.11K

-192.46%

Mr. Richard S. (Rich) Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

109.24K

-32.46%

Dr. Zsolt Harsanyi, Ph.D.

Independent Chairman of the Board

89.33K

-15.85%

Mr. Ronald B. Richard

Independent Director

64.02K

-22.12%

Ms. Jessica Perl

Senior Vice President, General Counsel, Corporate Secretary

61.00K

-10.60%

Ms. Coleen Glessner

Executive Vice President - Quality and Ethics and Compliance

55.82K

-5.97%

収益内訳

通貨: USD更新時刻: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

MCM Product sales

142.50M

61.66%

Commercial Product sales

74.90M

32.41%

Contracts and grants

13.70M

5.93%

地域別USD

会社名

収益

比率

U.S.Government

133.00M

57.55%

Non-U.S Government

98.10M

42.45%

事業別

地域別

事業別USD

会社名

収益

比率

MCM Product sales

142.50M

61.66%

Commercial Product sales

74.90M

32.41%

Contracts and grants

13.70M

5.93%

株主

更新時刻: Fri, Feb 27

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

7.60%

The Vanguard Group, Inc.

6.88%

State Street Investment Management (US)

5.22%

American Century Investment Management, Inc.

4.72%

Dimensional Fund Advisors, L.P.

4.36%

他の

71.22%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

7.60%

The Vanguard Group, Inc.

6.88%

State Street Investment Management (US)

5.22%

American Century Investment Management, Inc.

4.72%

Dimensional Fund Advisors, L.P.

4.36%

他の

71.22%

種類

株主統計

比率

Investment Advisor

36.55%

Investment Advisor/Hedge Fund

30.11%

Hedge Fund

8.75%

Research Firm

3.91%

Individual Investor

1.89%

Pension Fund

1.03%

Bank and Trust

0.64%

Family Office

0.06%

Insurance Company

0.04%

他の

17.03%

機関投資家保有株



更新時刻: Mon, Dec 8

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q4

378

39.86M

83.14%

+128.30K

2025Q3

417

39.73M

84.87%

+2.04M

2025Q2

439

37.58M

87.40%

+1.14M

2025Q1

454

36.44M

84.55%

-9.64M

2024Q4

461

35.04M

82.31%

+2.84M

2024Q3

467

32.21M

81.37%

+1.29M

2024Q2

485

30.86M

99.60%

-5.54M

2024Q1

494

36.44M

103.37%

-17.72M

2023Q4

512

41.89M

103.68%

-1.06M

2023Q3

563

42.52M

113.85%

-6.21M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

3.90M

7.43%

+75.52K

+1.97%

Sep 30, 2025

The Vanguard Group, Inc.

3.54M

6.74%

-43.54K

-1.21%

Sep 30, 2025

State Street Investment Management (US)

2.45M

4.66%

+705.00K

+40.50%

Sep 30, 2025

American Century Investment Management, Inc.

2.38M

4.54%

+90.22K

+3.94%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

2.14M

4.08%

+291.31K

+15.75%

Sep 30, 2025

Charles Schwab Investment Management, Inc.

1.38M

2.63%

+276.57K

+25.02%

Sep 30, 2025

Palisade Capital Management, LLC

1.43M

2.72%

+326.26K

+29.67%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.28M

2.43%

-305.00

-0.02%

Sep 30, 2025

Oak Hill Advisors, L.P.

1.11M

2.12%

--

Sep 30, 2025

Acadian Asset Management LLC

1.18M

2.24%

+203.07K

+20.84%

Sep 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

配当落ち日

種類

比率

データなし

日付

配当落ち日

種類

比率

データなし

Emergent BioSolutions Inc

詳細情報 Emergent BioSolutions Inc 企業名

Emergent BioSolutions Incの企業情報

Emergent BioSolutions Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割